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Physiological, hormonal, and genetic diﬀe r e n c e sb e t w e e nm a l e sa n df e m a l e sa ﬀect the prevalence, incidence, and severity of
diseases and responses to therapy. Understanding these diﬀerences is important for designing safe and eﬀective treatments. This
paper summarizes sex diﬀerences that impact drug disposition and includes a general comparison of clinical pharmacology as it
applies to men and women.
1.Introduction
At the core of personalized medicine is the identiﬁcation
of factors inﬂuencing disease processes and therapy [1,
2]. Consequently, characterizing the pharmacokinetics and
pharmacodynamics of a drug in diverse populations is essen-
tial in improving therapeutic eﬀectiveness while minimizing
adverse events [3]. For a drug to work, it is necessary to reach
and maintain a minimum drug concentration at the site(s)
of action. Exceeding the eﬀective concentration will increase
riskofadverseevents.Accordingly,drugconcentrationsmust
be maintained within a deﬁned therapeutic range.
Many factors inﬂuence circulating drug concentrations,
as well as the concentrations at the sites of action, and
determine the resulting outcome [4]. Sex, in particular, can
inﬂuence how the body handles a drug as well as what the
drug does to the body. This paper, which examines sex dif-
ferences in pharmacokinetics and pharmacodynamics, is an
update of current knowledge on this topic and includes peer-
reviewed literature published until October 2010 [5]. The
keywords used were: sex/gender diﬀerences, pharmacokinetics,
pharmacodynamics, adverse drug events, and sex diﬀerences
in drug metabolism/elimination. All reviewed manuscripts
pertain to publications concerning humans only, written and
published in the English language.
1.1. Gender Diﬀerences versus Sex Diﬀerences. Gender, a
social construct, is expressed in terms of masculinity and
femininity. It is deﬁned by the way people perceive them-
selvesandhowtheyexpectotherstobehave.Genderislargely
determined by culture. Sex diﬀerences result from the classi-
ﬁcation of organisms based on genetic composition as well
as reproductive organs and function [6]. Men and women
diﬀer in response to drug treatment and occupational expo-
sures, a consequence of diﬀerences in body weight, height,
body surface area, total body water, and the amount of
extracellular and intracellular water. Pharmacokinetics and
pharmacodynamics are also attributable to the diﬀerences
seen between males and females [5, 7–9].
1.2. General Background. Since pharmacokinetics, phar-
macodynamics, and responses during clinical trials diﬀer
between men and women, U.S. FDA regulations and guid-
ance are in place to ensure that both sexes are represented
in all phases of clinical trials and that medical products are2 Journal of Biomedicine and Biotechnology
labeled to alert physicians and patients to sex diﬀerences in
drug responses. In 1999, the National Institutes of Health
published the “Agenda for Research on Women’s Health for
the 21st Century,” concluding that sex-related diﬀerences in
pharmacokinetics and pharmacodynamics must be further
assessed.
In an eﬀort to overcome gaps in knowledge regarding the
actions of drugs in women, more women are now included
in clinical trials. The NIH Biennial Report of the Director
of 2006-2007 reported that in 2006, of 624 extramural and
intramural phase III clinical research protocols (499,430
participants), 63% were women [10, 11]. More attention is
currently being drawn towards the ways in which clinical
therapeutics can be tailored according to sex, age, body
weight, and genotype to yield the best possible outcomes
[12].
2. SexDifferences inAdverseEvents
The FDA Adverse Events Reporting System (AERS) is a
voluntary database of adverse events. Based on an analysis
of AERS data and other data resources, women experience
more adverse events than men, and in general, these adverse
eventsareofamoreseriousnature[13–17].TheU.S.General
Accounting Oﬃce (GAO) reviewed the ten drugs withdrawn
from the market during the period January 1, 1997 through
December 2000; eight of the ten were withdrawn due to
greater risks of adverse eﬀects in women [18].
Sex-related diﬀerences in the frequencies of adverse
events reporting may be due to pharmacokinetic or pharma-
codynamicfactors,polypharmacy,ordiﬀerencesinreporting
patterns [19]( Table 1). Women are generally smaller and
have a diﬀerent body composition than men, the recom-
mended dose may result in higher drug concentrations or
area under the concentration time curve (AUC) in women
because the drug has lower clearance and/or smaller volume
of distribution (Vd)[ 20]. Alternatively, pharmacodynamic
factors (alterations in drug-target numbers or responses)
may increase female sensitivity to speciﬁc drugs [21]. In
this instance, free drug concentrations and drug persistence
would be similar in men and women, but women would
respondtoagreaterorlesserextent.Itisalsopossiblethatsex
diﬀerences between men and women result in similar rates
of adverse events but that women experience more severe
events. Another plausible explanation might be attributed to
prescribing patterns; women ingest more medications than
men, increasing the risk of adverse events from drug-drug
interactions.
3. SexDifferences inPharmacokinetics
3.1. Drug Absorption and Bioavailability. Drug absorption
and bioavailability are inﬂuenced by drug- and route-
speciﬁc factors (oral, dermal, rectal, vaginal, intramuscular,
intravenous, intra-arterial, intrathecal, and intraperitoneal).
Routes of absorption occur across body surfaces, such as
the gastrointestinal tract, respiratory tract, or skin, which
diﬀer in males and females. For example, drug absorption
occurs at diﬀerent sites throughout the gastrointestinal tract,
and rate of absorption is inﬂuenced by gut transit times,
lipid solubility of the agent, pH at the site of absorption,
and the ionization and molecular weight of the agent [5].
Transit times diﬀer signiﬁcantly in men and women, with
mean transit times being shorter in men (44.8 hours) than
in women (91.7 hours) [22]. While ﬁber ingestion decreases
transit time, female gut transit times are consistently longer
[22]. Sex diﬀerences have also been noted in bile acid
composition, which may impact the solubility of various
drugs. Men have higher concentrations of cholic acid, while
womenhavehigherconcentrationsofchenodeoxycholicacid
[23].
The FDA evaluated sex diﬀerences in bioequivalence
among 26 studies submitted to the agency between 1977 and
1995[20,24].Itisamajorconcernthatovera20-yearperiod,
only26studiessubmittedtotheFDAhaddataaddressingsex
diﬀerences in drug absorption. Among the 26 studies, there
were 47 datasets addressing sex diﬀerences in maximum
concentration (Cmax) and AUC. None of the datasets had
morethan20individualsofeachsex.Mosthadnomorethan
10 men or women, so the sample size available to assess sex
diﬀerences in bioavailability was limited. However, among
these studies, the Cmax was greater in women 87% of the
time and AUC was greater in women 71% of the time.
Other investigators have utilized multidrug cocktails
to assess bioavailability and metabolism across age and
sex [25]. The advantage of this approach is the ability
to phenotype multiple cytochrome P450 (CYP) enzymes
including CYP1A2, 2C19, 2D6, 2E1, and 3A4 (although dif-
ferences in intestinal and hepatic metabolism and transport
may complicate the interpretation of the data). Using this
approach, the investigators suggested that the activities of
CYPs 2C19, 2D6, and 3A4 were equivalent and that the
activities of CYPs 1A2 and 2E1 were decreased in women
than in men. However, using well-characterized human liver
samples, another group of investigators observed ∼2-fold
greater hepatic CYP3A4 activity in women, suggesting sex
diﬀerences in ﬁrst pass metabolism and bioavailability [26].
Analysis of 24 studies of CYP3A4 substrates observed that
clearance was greater in women than men for 15 substrates
(60%) [27]. These divergent data suggest that sex diﬀerences
in absorption and bioavailability remain unresolved.
In addition to sex diﬀerences in bioavailability, it is
important to consider that food interactions (e.g., grapefruit
juice), gut motility and transit time, gut pH, biliary secretion
and gut ﬂora, enterohepatic circulation and oral contracep-
tives can diﬀerentially inﬂuence the bioavailability of a drug
in men and women [28, 29]. For example, it was recently
observed that polyethylene glycol enhances the bioavailabil-
ity of ranitidine in men and decreases it in women [30].
Sex diﬀerences in bioavailability of Cyclosporine A have also
been observed after a fat-rich meal: decreased bioavailability
in females and increased bioavailability in males [31]. It
has been hypothesized that, because of diﬀerences in sub-
cutaneous lipid content, the bioavailability of transdermally
administered drugs is diﬀerent in women [32]. Additionally,
womenhavegreaterrespiratoryminuteventilationandlower
tidal volume, which may result in decreased ingestion ofJournal of Biomedicine and Biotechnology 3
Table 1: Suggested reasons for sex diﬀerences in adverse event reporting.
Reason for sex diﬀerence Pharmacological reason Pharmacological factors
Women are overdosed Pharmacokinetics
Sex diﬀerences in volume of distribution
Sex diﬀerences in protein binding of drugs
Sex diﬀerences in transport, phase 1, and phase 2 metabolism
Women are more sensitive Pharmacodynamics
Sex diﬀerences in drug targets
(i) receptor number
(ii) receptor binding
(iii) signal transduction following receptor binding
Women are prescribed multiple
medications
Drug-drug interactions
Drug-drug induced alterations
Pharmacokinetics
Pharmacodynamics
(Table modiﬁed from Soldin and Mattison [5]).
inhaled aerosol drugs, such as ribavirin and cyclosporine,
although only limited data are available so far [23, 33].
3.1.1. Gastric and Hepatic Enzymes. An important part of
bioavailability includes the gastric and hepatic enzymes
and transport proteins that oral drugs interact with prior
to reaching the systemic circulation [34, 35]. Gastric and
hepatic enzymes and transporters change across the course
of development, forming the basis for sex diﬀerences [36].
These metabolic and transport processes are critical for the
success or failure of drugs developed for oral use [35].
Successful oral drugs are soluble, permeable, and poorly
metabolized by intestinal and hepatic enzymes. For example,
the bioavailability of alcohol is greater in women than in
men, with Cmax and AUC being greater. These can be
partly ascribed to diﬀerences in Vd and gastric alcohol
dehydrogenase activity [37].
3.1.2. Transport Proteins. Transport proteins play a critical
role in transporting drugs into and out of all cells and are
consequentlyinvolvedinhepatobiliaryandurinaryexcretion
[34]. Tissue distribution and elimination pathways, as well
as eﬃcacy and toxicity of drugs, are explained in many
cases by transport proteins. One interesting example is
paclitaxel neurotoxicity, which appears to be dependent on
phenotypic and genotypic variation in CYP3A4/5, as well
as transport proteins (OATP 1B1/3 and PGP), which vary
with sex [38]. Variability in the intestinal expression of
transport proteins may result in sex diﬀerences in plasma
drug concentrations. For example, p-glycoprotein (PGP),
a membrane adenosine triphosphatase transporter protein
found in high concentrations in the enterocytes of the small
intestine, is encoded by the multidrug resistance transporter-
1 gene (MDR1) expressed in the human intestine, liver and
other tissues [39]. PGP, expressed in higher numbers in men,
has been shown to decrease intracellular concentrations of
certain drugs at the intestine by transporting them out of
the enterocytes and back into the intestinal lumen. This
mechanism results in the drug being repeatedly exposed
to intestinal drug-metabolizing enzymes [23, 40]. Synthetic
and endogenous sex hormones have been shown to regulate
PGP expression and inhibit PGP function at the gut wall,
enhancing drug absorption [41]. Absorptive transporters
such as H+/ditripeptide transporter and organic anion
transporting polypeptide (OATP) facilitate drug absorption,
while eﬄux transporters such as PGP sometimes work as
drug absorption barriers [42].
Sex diﬀerences are also exhibited by the serotonin 5-
HT1A receptor and serotonin transporter (5-HTT), which is
a target for selective serotonin reuptake inhibitors (SSRIs),
psychotropic drugs used in the treatment of depression,
anxiety, and personality disorders. Women have signiﬁcantly
higher 5-HT1A receptor and lower 5-HTT binding potentials
throughout the cortical and subcortical brain regions and
exhibit a positive correlation between 5-HT1A receptor and
5-HTT binding potentials for the hippocampus. Thus, sex
diﬀerences in 5-HT1A receptor and 5-HTT binding poten-
tials may result in biological distinctions in the serotonin
system, thereby contributing to sex diﬀerences in the preva-
lence of psychiatric disorders such as depression and anxiety
[43].
3.1.3. Enterohepatic and Renal Handling of Drugs or Metabo-
lites. Gastric ﬂuids are generally more acidic in males than
females (pH 1.92 versus pH 2.59), and basal and maximal
ﬂowofgastricﬂuidandacidsecretionarebothhigherinmen
[44]. Reduced pH results in decreased absorption of weak
acidsandincreasedabsorptionofweakbases.Theabsorption
of antidepressants, the majority of which are weak bases,
is greatly increased in women, further enhanced by slower
rates of gastric emptying and prolonged gut transit times
[45].
The kidneys are responsible for the maintenance of
water/electrolyte balance, the synthesis, metabolism, and
secretion of hormones, and excretion of waste products from
metabolism as well as most drugs and xenobiotics. The
human kidney demonstrates sex-related diﬀerences in the
subunits of glutathione-S-transferase isoenzyme [46].
Iron also has signiﬁcant diﬀerences between males and
females in gastrointestinal absorption. In preadolescent
males and females, it has been shown that 45% of ingested
iron is incorporated into erythrocytes by females compared
to 35% in males (iron-regulated surface determinant −0.78)
[47, 48].4 Journal of Biomedicine and Biotechnology
3.2. Distribution. Once absorbed and in the circulation,
most drugs bind to plasma proteins. Distribution is a
function of multiple physiologic and body composition
characteristics. Sex diﬀerences in these parameters may
account for diﬀerences in the concentration of a drug at
the target site and result in varying responses. However,
diﬀerences in protein binding between men and women are
generally rare, and there is still no convincing link between
protein-binding diﬀerences and sex-speciﬁc ADRs, with the
exception of lignocaine and diazepam [48]. On average,
total body water, extracellular water, intracellular water, total
blood volume, plasma volume, and red blood cell volume
are greater for men. Therefore, if an average man and an
average woman are exposed to the same dose of a water-
solubledrug,Vd willbeincreasedintheman,thusdecreasing
drug concentration.
For lipid-soluble drugs, there is generallyan increasedVd
in females. Alcohol, a water-soluble drug, has a smaller Vd
in women than in men, producing higher Cmax in women
[49]. The Vd values of salbutamol (albuterol) and oﬂoxacin
have been shown to be signiﬁcantly greater in men, most
likely due to sex diﬀerences in lean body mass [50]. The
liver accounts for a greater percentage of lean body mass in
women compared to men. It is currently believed that the
largerlivermassandsmallerVd observedinwomenaccounts
for the more rapid rate of elimination of alcohol from the
blood [51].
Sex diﬀerences in blood distribution and regional blood
ﬂow can also impact pharmacokinetics. In general, the
reference values for resting blood ﬂow to organs and
tissues for 35-year-old males and females show signiﬁcant
diﬀerences as a percentage of cardiac output. For example,
blood ﬂow to skeletal muscle is greater for men and to
adipose tissue is greater for women. These diﬀerences may
reﬂect sexbased diﬀerences in the percentage of total body
mass represented by each tissue [52]. Blood distribution will
also impact clearance rates. Females exhibit decreased liver
blood ﬂow rates which, despite higher CYP3A4 amounts and
activity, may result in lower drug clearance [45].
The main binding proteins for various drugs in plasma
are albumin, α1- a c i dg l y c o p r o t e i n( A A G ) ,a n dα globulins.
AAG levels and AAG glycosylations vary in association
with endogenous and exogenous estrogen, inducing hepatic
glycosylation of these proteins and thus decreasing plasma
AAG levels. Albumin concentrations do not consistently
vary by sex [53]. Estrogens also increase the levels of the
serum-binding globulins (sex-hormone-binding globulin,
corticosteroid-binding globulin, and thyroxin-binding glob-
ulin) [54]. Sex-related diﬀerences in plasma binding of
selected compounds are listed in Table 2.V a r i a t i o n si nl e v e l s
ofplasmabindingcanalterthefree(active)fractionofdrugs.
Therapeutic drug monitoring is the measurement of
speciﬁc drugs in order to maintain a relatively constant
circulating drug concentration. Drugs that are monitored
tend to have a narrow “therapeutic range”—the drug
quantity required to be eﬀective is not far removed from
the quantity that causes signiﬁcant side eﬀects and/or signs
of toxicity. Maintaining drug concentrations within the
therapeutic range is not as simple as giving a standard dose
Table 2: Sex diﬀerences in plasma binding.
Compound Description
Testosterone Plasma protein binding: F > M, Estrogen
increases
Chlordiazepoxide Plasma protein binding: M > F > Foc
Diazepam Free fraction: Foc (1.99%) > F (1.67%) >
M (1.46%)
Lidocaine Free fraction: F (34%), M (32%) < Foc
(37%)
Warfarin Free fraction: F > M
Morphine, Phenytoin
Oxazepam, Lorazepam No diﬀerences
oc: oral contraceptives.
Table modiﬁed from Soldin and Mattison [5].
of medication. Often, if the free fraction increases, there is
a shift of the drug to the tissues/target or resultant higher
clearance, with the total concentration not changing, for
example, phenytoin.
3.2.1. Body Composition. Body fat as a percentage of total
body weight is higher in women than in men and increases
by age in both sexes [55]. The total body fat values are
13.5kg in an adult reference male and 16.5kg for an adult
reference female [56]. The larger proportions of body fat in
women may increase the body burden of lipidsoluble, slowly
metabolized toxicants. Diﬀerences in body fat and in organ
blood ﬂow in women have been implicated in the faster
onset of action and prolonged duration of neuromuscular
blockade in women (e.g., vecuronium and rocuronium) [57,
58]. Diﬀerences in body fat content and in protein binding
are responsible for sex-related pharmacokinetic diﬀerences
in the distribution of diazepam (free fraction: in females
1.67% versus 1.46% in males). Females have been shown to
have larger Vd than males (Vd = 1.87 versus 1.34L/kg) [59].
S e v e r a ls t u d i e sh a v eo b s e r v e dt h a tw h e nd o s ei sc o r -
rected by body weight, some of the sex diﬀerences seen in
pharmacokinetics disappear [20]. This suggests body weight
(andbyinference,composition)mayberesponsibleforsome
diﬀerencesseenindrugdisposition.Arecentstudyexamined
the plasma concentrations of the antibiotic clindamycin
in twenty-four male and female subjects. Higher plasma
concentrations were seen in women. However, when the
600mg dose was normalized to individual body weight,
plasma concentrations between men and women were com-
parable [60]. Aliskirin, an antihypertensive rennin inhibitor,
as well as ﬂuconazole, an antifungal drug, both appear
to require dosage adjustments by body weight [61, 62].
Furthermore, the pharmacokinetics of citalopram does not
display diﬀerencesbetween malesand femaleswhenadjusted
by dose and body weight [63].
3.2.2. Cardiac Output. Cardiac output and regional distri-
bution of ﬂow are important for drug disposition. Cardiac
outputiscommonlystandardizedandreportedasthecardiac
index,whichissimilarforbothsexesbetween18and44yearsJournal of Biomedicine and Biotechnology 5
of age. The distribution of cardiac output, or regional blood
ﬂow, is similar for men and women for some organs (adrenal
0.3%, bone 5%, brain 12%, lung 2.5%, skin 5%, and thyroid
1.5%,reportedaspercentofcardiacoutput)anddiﬀerentfor
others(adipose:male=5%,female=8.5%;heart:male=4%,
female = 5%; kidney: male = 19%, female = 1 7 % ;l i v e r :m a l e
= 25%, female = 27%; muscle: male = 17%, female = 12%),
reﬂecting sex-based diﬀerences in body composition [64].
3.3. Drug Metabolism. Drug metabolism (biotransforma-
tion) occurs predominantly in the liver, as well as in
extrahepatic sites such as the intestinal tract, lung, kidney,
and skin. Hepatocytes and intestinal cells express signiﬁcant
levels of CYP3A and phase II enzymes such as uridine
diphosphate glucoronosyltransferase (UGT), which may
signiﬁcantly contribute to the ﬁrst pass metabolism of many
orally administered drugs (see discussion above on bioavail-
ability). Lipid solubility, protein binding, the dose, and the
route of exposure all aﬀect the rate of biotransformation.
Despite the large variations in drug metabolism among
individuals, correction for height, weight, surface area, and
body composition eliminates some but not all of the “sex-
dependent” diﬀerences. However, sex-dependent diﬀerences
in biotransformation have been observed for drugs such as
nicotine, chlordiazepoxide, ﬂurazepam, aspirin (acetylsali-
cylic acid), and heparin [65–69].
3.3.1. Cytochrome P450 (CYP) Group. The main enzymes
involved in drug metabolism belong to the CYPs. These are
a large family of related enzymes housed in the smooth
endoplasmic reticulum of the cell. While the CYP enzymes
discussed in this paper are all coded for by autosomal
chromosomes, it is possible that sex-related disparities in
pharmacokinetics arise from variations in the regulation
of the expression and activity of CYP enzymes through
endogenous hormonal inﬂuences. For reviews that deal
speciﬁcally with CYP enzymes, please refer to [23, 70–76].
3.3.2. Hepatic and Extrahepatic Metabolism. Ingested com-
pounds may remain unchanged (and possibly accumulate
in a storage compartment) or, based on their degree of
lipophilicityandpolarity,theymaybesubjecttometabolism.
Hepatic drug metabolism is divided into two usually sequen-
tial enzymatic reactions: phase I and phase II reactions.
Some of the CYP enzymes show clear sex-related diﬀerences
(Table 3). In general, lipophilic compounds have a tendency
to pass through biological membranes and/or be stored and
are often susceptible to phase I types of metabolism [77].
Sex-related diﬀerences have been shown for some CYPs,
with a higher activity in females for CYP3A4 (Table 3)
[78]. An analysis of previously published studies of 14
diﬀerent drugs demonstrated that females displayed an
average of 20–30% increased clearance for drugs that were
CYP3A substrates compared to those of males [27]. In
2009, Lutz and colleagues demonstrated for the ﬁrst time
in a Caucasian population that the endogenous marker for
CYP3A activity—the metabolic ratio of 6 β-hydroxycortisol
to cortisol found in urine—was signiﬁcantly increased in
females compared to males [79].
By studying the activity of sex hormones, as a conse-
quence of physiological, pathological, or pharmacological
manipulations, researchers now believe that many of the
changes seen in CYP enzymes may be gender speciﬁc [36].
The sex-dependent expression of CYP3A4 is thought to be
regulated by sex-speciﬁc temporal patterns of plasma growth
hormone release by the pituitary gland. Males display a
pulsatile pattern while females exhibit a more continuous
pattern of release. Growth hormone regulation of CYP3A4
has been discerned in primary human hepatocyte cultures;
CYP3A4 protein and mRNA are induced by continuous
treatment with growth hormone and suppressed with pul-
satiletreatment[80].CYP3A4activity,however,hasnotbeen
seen to vary throughout the menstrual cycle, suggesting that
sex hormones may not be responsible for the gender-speciﬁc
expression observed [23].
Antihistamines, in particular, have been shown to exhibit
sex-speciﬁc diﬀerences in pharmacokinetics. They act as
CYP2D6substrates,whichhavebeenshowntoexhibitslower
metabolic elimination in women. This may explain why
women are more vulnerable to sedation and drowsiness
eﬀects of antihistamines than men. Gender diﬀerences in
PGP expression in the brain may also underlie the sedative
side eﬀects often experienced by women [23].
H o w e v e r ,e v e ni ft h e r ea r et r u es e xd i ﬀerences in
drug pharmacokinetics, only few drugs exhibit signiﬁcantly
diﬀerent plasma concentrations in women. A comprehen-
sive review of second-generation (atypical) antipsychotics
concludes that even though sex diﬀerences in cases of
adverse events have not been well studied, some adverse
eﬀects such as weight gain, hyperprolactinemia, and car-
diac eﬀects, are particularly problematic for women [81].
Most studies that were reviewed indicate that clozapine
and olanzapine are associated with greater body weight
gain than other atypical antipsychotics and that serious
adverse eﬀects such as metabolic syndrome (which includes
increased visceral adiposity, hyperglycemia, hypertension
and dyslipidemia induced by atypical antipsychotics) are
more frequent in females. Although women are at a lower
risk of sudden cardiac death, they have a higher risk
of induced long-QT syndrome from antiarrhythmic and,
probably, antipsychotic drugs [82, 83]. This adverse eﬀect
has been seen with drugs that block cardiac voltage-gated
potassium channels, prolonging repolarization and the QT
interval [23].
Metabolism of chemicals may be estimated by basal
metabolic rates. For all ages, on average, men have a higher
basal metabolic rate than women. Since the metabolism of
adipose tissue diﬀers from that of muscle tissue, some of the
diﬀerencesbetweenmenandwomenareattributabletobody
compositionmetabolismofadiposetissue[84].Alowerbasal
metabolic rate per unit body surface area reﬂects the lower
lean body mass in women due to a smaller skeletal muscle
component [85].
Hepatic clearance of drugs is a function of liver blood
ﬂow and hepatic enzyme activity. Although cardiac output
and hepatic blood ﬂow are lower in women than in men6 Journal of Biomedicine and Biotechnology
Table 3: Sex diﬀerences in hepatic clearance by route of metabolism/elimination.
Phase I Enzymes
Metabolic route Model substrates Drugs metabolized by route Sex-speciﬁc
activity
CYP1A Caﬀeine, nicotine paracetamol
(acetaminophen)
Clomipramine, clozapine, olanzapine, paracetamol, tacrine,
theophylline M > F[ 65]
CYP2C9 Dapsone, (S)-mephenytoin
Ibuprofen, (S)-warfarin, tolbutamide, ﬂuvastatin, glipizide,
losartan, irbesartan, piroxicam, tolbutamide, phenytoin,
ﬂuvastatin, nelﬁnavir
M=F[ 66]
CYP2C19 (S)-Mephenytoin Diazepam
Lansoprazole, omeprazole, hexobarbital, mephobarbital,
citalopram, celecoxib, irbesartan, imipramine, piroxicam,
propranolol (in part)
M=F[ 67]
CYP2D6 Dextromethorphan,
debrisoquine, sparteine
Codeine, encainide, ﬂecainide, ﬂuoxetine, hydrocodone,
metoprolol, paroxetine, mexilitine, phenformin,
propranolol, sertraline, timolol, haloperidol, clomipramine,
desipramine, imipramine, propafenone, testosterone
M < F[ 68]
CYP2E1 Chlorzoxazone —M > F[ 69]
CYP3A
Midazolam, dapsone, cortisol,
Lidocaine, nifedipine,
erythromycin
Alprazolam, alfentanil, astemizole, atorvastatin,
carbamazepine, cisapride, clarithromycin, cyclosporin,
cyclophosphamide, diazepam,diltiazem, erythromycin,
estradiol, fentanyl, indinavir, itraconazole, ketoconazole,
lovastatin, quinidine, nimodipine, nisoldipine, quinidine,
ritonavir, verapamil, tacrolimus, simvastatin, vincristine,
vinblastine, tamoxifen, tirilazad, troglitazone
F > M[ 70]
Phase II enzymes
Metabolic route Model substrates Drugs metabolized by route Sex-speciﬁc
activity
UDP-glucuronosyl-
transferases Caﬀeine Cloﬁbric acid, diﬂusinal, ibuprofen, mycophenolate,
mofetil, paracetamol, zidovudine M=F[ 68, 71]
Sulfotransferases Caﬀeine — M > F[ 72]
N-Acetyl-transferases Caﬀeine, dapsone Catecholamine derivatives, mercaptopurine, isoniazid,
hydralazine M=F[ 73]
Methyl-transferases Norepinehrine, epinephrine Azathioprine, dopamine, levodopa, 6-mercaptopurine,
thioguanine, tazathioprine M > F[ 74]
Table modiﬁed from Soldin and Mattison [5].
normalized per m2/kg, sex diﬀerences in hepatic enzymes
also play a major role in determining sex-related pharma-
cokinetic activity. At the canalicular surface of hepatocytes,
PGP will direct the biliary excretion of certain drugs, and its
expression has been found to be twofold lower in women
than in men. Consequently, women display increased and
sustained intracellular concentrations of PGP substrates,
increased activity of hepatic drug-metabolizing enzymes,
and thus increased clearance of the drug [23]. Much is
unknown regarding PGP expression although it is currently
thought to be controlled and regulated by sex hormones.
3.4. Drug Elimination. Two processes, metabolism and elim-
ination, are responsible either separately or together for
drug inactivation. Without these means, drugs would con-
tinuously circulate throughout our bodies, bind to various
receptors, and interrupt important physiological processes.
Drugs are generally eliminated from the body by renal,
hepatic, or pulmonary routes. Consequently, drugs may be
eliminated from the body in sweat, tears, breast milk, and
expired air. The most common routes are via feces and
urine.
The kidney is the major organ of drug excretion of
either the parent drug compounds or drug metabolites.
There are known sex diﬀerences in all three major renal
functions-glomerular ﬁltration, tubular secretion and tubu-
lar reabsorption. Renal clearance is generally higher in men
[86, 87]. A recent study on the transdermal absorption
of fentanyl, a pain management drug for cancer patients,
found that particularly at high doses, urinary excretion of
fentanyl was markedly decreased in women. Gender also
has a signiﬁcant impact on the elimination of the loop
diuretic torasemide, contributing to higher rates of adverse
drug reactions in women. Hospitalizations due to ADRs
from diuretics are more prevalent in women, irrespective
of diﬀerences in prescription rates between the sexes [88].
Adjusting for age, body mass index (BMI), and modiﬁcation
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was on average one-third lower in women, associated with
30%–40% higher mean AUC24 and Cmax values in females
than in males [88].
Renal function is important for elimination. Chemicals
can be excreted into the urine through glomerular ﬁltration,
passive diﬀusion, and active secretion. Increases in renal
blood ﬂow and glomerular ﬁltration increase the elimination
rate of drugs cleared by the kidneys. When standardized for
body surface area, renal blood ﬂow, glomerular ﬁltration,
tubular secretion, and tubular reabsorption are all greater in
men than in women [89, 90].
3.5. Anesthesia and Opioids. Sex-dependent diﬀerences
among the three primary opioid receptor subtypes—mu,
delta, and kappa—have been extensively studied. The kappa
opioid receptor subtype may be sex-dependently modulated
by Mc1r, a gene that encodes for melanocortin-1 receptors.
Women with two or more variant alleles of this gene were
more responsive to pentazocine than women with one or
no variants of the gene. This antinociceptive phenomenon
was not seen in men [91]. Morphine, a mu-opioid receptor
agonist, has been shown to be more potent and also exhibits
a slower onset and oﬀset in women [92]. Additionally,
women perceived more pain and required greater dosages
of morphine to achieve the same antinociceptive eﬀect
as men [93]. This may be explained by the higher mu-
opioid receptor binding in various cortical and subcortical
brain regions exhibited in women than in men. According
to a 2009 comprehensive review on sex-speciﬁc inﬂuences
on pain, women appear to be not only more sensitive to
pain but also more vulnerable to chronic, widespread, and
postproceduralpainconditions[94].Designingandtailoring
treatment plans for pain may certainly need to take sex into
account.
3.6. Self-Administered Drugs. Sex diﬀerences in pharmacoki-
netics of self administered drugs and in drug dependence
have also been explored. Biologically, it is believed that sex
and gonadal hormones underlie many of the diﬀerences seen
in drug sensitivity, addictive behavior, and susceptibility to
drug abuse. In general, women appear to be more vulnerable
to the rewarding and dependent properties of cannabinoids,
alcohol, opioids, and cocaine. Many animal models of
genderinﬂuencesonsubstanceabusehaveconﬁrmedclinical
ﬁndings [95]. With an ever-growing population using self-
administered drugs and the pressing need to eﬀectively
address and treat substance abuse, larger clinical studies
focusing on this topic must be carried out.
4. Sex Differences inPharmacodynamics
For cortisol and ﬁrst-generation antihistamines, there
appears to be signiﬁcant sex diﬀerences in pharmacody-
namics. Because women are more sensitive to cortisol
suppression, they may also be more sensitive to the eﬀects
on basophils and helper T lymphocytes [96–98]. This is
interesting because of the balance in sex diﬀerences in
both pharmacokinetics and pharmacodynamics, suggesting
that men and women should receive the same dose and
treatment schedule. A recent epidemiological study showed
thatwomenbeingtreatedforallergicdiseasesdisplaylowered
levels of eosinophils and IgE than men [23]. Additionally,
there appear to be a lower expression of ERK/MAPK
signaling genes, leukocyte extravasation, antigen presen-
tation, and chemokine signaling in women than in men
[23]. Sex diﬀerences in pharmacodynamics may also aﬀect
cardiovascularmedications.Digoxintherapyhasbeenshown
to diﬀer by sex and was associated with an increase in all-
cause death among women [99].
5. Sex-SpeciﬁcConditions That Impact
Pharmacokinetics andPharmacodynamics
5.1. Inﬂuence of Sex Hormones. There are numerous exam-
ples supporting the contention that female sex hormones
impact drug-metabolizing pathways. For example, drug-
induced long QT syndrome has a higher rate of incidence
in females, particularly during the ovulatory phase of the
menstrual cycle compared to the luteal phase [100]. It has
been established that there exists a basal sex hormonal
regulatory impact on cardiac potassium channels and that in
drug-induced QT prolongation, drug-hormone interactions
seen at particular doses cause a blockade in these channels
[101–103]. Heightened sensitivity to opioids in females
has been consistently observed. We now know that opioid
receptor density and dopaminergic function is inﬂuenced by
femalehormones,leadingtoahigherrateofADRsinwomen
under anesthesia [104], such as diﬃculties in respiration and
increased chronic pain. Moreover, sex hormones have also
beenimplicatedinfunctionalalteringofGABAreceptors,the
target of anesthetic drugs [105].
Estrogen has membrane, cytosolic, and nuclear targets
[106]. Estrogen has been shown to bind and modulate
membrane ion channels and receptors, such as cardiac
ATP-K+ cardiac channels and opioid receptors. The estro-
gen receptor is a cytosolic target which serves to trigger
downstream kinase activation [107]. Nuclear targets include
hormone receptors such as ERα, which directly modulates
CYP1B1 expression [108]. A recent review on sex diﬀerences
in pharmacokinetics of antidepressants highlights possible
hormone-drug competition for hepatic metabolic enzymes.
Since estrogen is a substrate for CYP3A4 and CYP1A2,
antidepressant metabolism may be signiﬁcantly impacted
during the late luteal phase of the menstrual cycle or with
estrogen replacement therapy [45].
5.2. Changes in Sex Hormone Levels. Increased levels of
estrogen and progesterone alter hepatic enzyme activity,
which can increase drug accumulation or decrease elimina-
tion of some drugs. Female steroid hormones and prolactin
play a role in autoimmunity. Regulation of immunity and
interactions between the hypothalamic-pituitary-adrenal
and hypothalamic-pituitary-gonadal axes contribute to
the 2- to 10-fold incidence and severity of autoimmune/
inﬂammatory diseases in females compared to males.
Most autoimmune diseases are detected in females of8 Journal of Biomedicine and Biotechnology
Table 4: Some drugs that display sex diﬀerences in pharmacokinetics.∗
Drug Pharmacokinetic parameter Comments
Acebutolol [76] Area under the concentration-time
curve
The concentration-time proﬁle is larger in women,
suggesting greater therapeutic and potential side eﬀects
Aspirin [36] Clearance, half-life Aspirin is cleared more rapidly from women
Benzylamine Following transdermal absorption, women excrete 3 times
more than men
Beta-Blockers;
Atenolol [77]
Oral clearance lower in women, lower
volume of distribution in women
resulting in higher systemic exposure
The greater reduction in blood pressure in women was due
to pharmacokinetic and not pharmacodynamic diﬀerences
Cefotaxime [79] Clearance Clearance is decreased in women
Ciproﬂoxacin [80] Clearance Clearance is lower in women
Cephradine [81]
Slower rate of absorption and lower bioavailability in the
female; increased clearance and decreased terminal
elimination half-life in pregnancy
Clozapine [82] signiﬁcantly higher plasma levels for women
Diazepam [83] Plasma binding Larger volume of distribution in women
Ethanol [86] Volume of distribution, clearance,
and ﬁrst-pass metabolism
When ethanol is ingested, men metabolize more in ﬁrst pass
metabolism; in addition the volume of distribution is
smaller in women
Ferrous Sulfate Absorption Absorption higher in prepubertal girls than boys
Fluoroquinolones [87] Volume of distribution Lower in women
Gemcitabine [79] Clearance Clearance is lower in women
Heparin [79] Clearance Clearance is lower in women
Iron [79] Absorption measured as % of the
dose incorporated into red blood cells More ingested iron is absorbed by women than men
Methylprednisolone [90] Plasma binding, clearance, volume of
distribution, and half-life
Plasma binding and Vd are similar in men and women; CL is
increased in women and as a consequence, half-life is shorter
Metronidazole Volume of distribution Smaller volume of distribution and increased clearance
resulting in lower AUC in women
Metoprolol [100] Plasma binding, clearance, volume of
distribution, half-life
Clearance increases during pregnancy, but is smaller in
women;
Vd smaller in women than men, but increases during
pregnancy;
plasma binding is unaﬀected by sex or pregnancy
Midazolam [101] Considered to be probe for CYP3A4,
not substrate for PGP
No sex diﬀerence in clearance following either oral or
intramuscular administration; interpretation complicated
by diﬀerences in intestinal and hepatic CYP3A4 levels
Mizolastin [102] Oral availability Longer duration for absorption in men, contributing to
variability in drug concentrations in men and women
Naratriptan [79] Oral availability, peak concentration Oral bioavailability being greater in women results in peak
concentration is higher in women than men
Oﬂoxacin Clearance Clearance is lower in women
Olanzapine [103] Higher activity in women for
CYP3A4 and CYP2D6 Signiﬁcantly higher plasma levels for women
Ondansetron [79] Oral availability, clearance Oral availability is increased in women
Phenytoin [104] Plasma binding
Plasma binding decreases during pregnancy; however, the
intrinsic clearance is unchanged so the free concentration is
unchangedJournal of Biomedicine and Biotechnology 9
Table 4: Continued.
Drug Pharmacokinetic parameter Comments
Prednisolone [105] Distribution Oral clearance and volume of distribution signiﬁcantly
higher in men
Propranolol [106] Plasma binding, clearance, volume of
distribution, and half-life
Plasma binding is similar among men and women; however,
plasma binding increases during pregnancy. Clearance is
smaller in women. Vd is similar in both men and women
and does not appear to be altered during pregnancy.
Half-life is decreased in women compared to men but does
not appear to be altered during pregnancy
Quinine [79] Plasma binding, clearance, volume of
distribution, and half-life
Plasma binding is unaltered during pregnancy, as is
clearance.
Vd decreases during pregnancy, as does half-life
Rifampicin [9] Women absorb the drug more
eﬃciently —
Rizatriptan [79] Urinary excretion, clearance, volume
of distribution, half-life
Urinary excretion is similar in men and women; clearance is
greater in men
Rocuronium Distribution Prolonged drug duration due to higher fat content and
lower organ blood ﬂow in women
Salicylate [108] Absorption Increased rates of absorption in women
Selective Serotonin
Reuptake
Inhibitors [91]
Plasma concentrations are higher in
women Decreased metabolism by hepatic CYP
Vecuronium Distribution Prolonged drug duration due to higher fat content and
lower organ blood ﬂow in women
Verapamil; Calcium
channel blocker [94, 95]
Clearance following intravenous
administration more rapid in
women, but oral clearance higher in
men than women. Substrate for both
CYP3A4 and PGP
Sex diﬀerences in hepatic and gut CYP3A4 and PGP lead to
complex diﬀerences in clearance between men and women.
Bioavailability from the gut is greater in women. The greater
bioavailability leads to increased systemic exposure in
women
Oral clearance is lower in women
∗Pregnancy-related PK changes are in italics font.
Table modiﬁed from Soldin and Mattison [5].
childbearing age. Metabolic changes can also depend on
hormone levels that change during the menstrual cycle,
with use of oral contraceptives, throughout pregnancy, or
during menopause. For example, some asthmatic women
have worsening symptoms before or during menstruation
[109]. An increase in oxidative stress in females has been
described during intensive physical exercise, particularly
in postmenopausal women [110]. Moreover, sex hormone
levels throughout the menstrual cycle are associated with
the activation of speciﬁc hepatic enzymes and the rate
of clearance of certain drugs. Caﬀeine and theophylline
clearance, for example, is higher during the early
follicular phase and prolonged during the mid-luteal phase
[39].
Although sex hormones are thought to play a dominant
role in modulating sex-based diﬀerences in pharmacokinet-
ics, studies examining this have yielded conﬂicting results.
Midazolam clearance (reﬂecting CYP3A4 metabolic activity)
failed to show ﬂuctuations during the menstrual cycle [111].
Similarly, studies of eletriptan (to treat migraines) demon-
strated no sex-related or menstrual cycle-related diﬀerences
[112].
5.3. Menopause. There are conﬂicting data that exist on
pharmacokinetic changes in women relating to menopausal
status. To examine menopause-related alterations in intesti-
nal or hepatic CYP3A4 activity, several studies compared
the pharmacokinetics of midazolam, erythromycin, and
prednisolone clearance in pre- and postmenopausal women
and found no signiﬁcant diﬀerences in drug metabolism
according to menopausal status [113].
5.4. Use of Data in Pharmacokinetics. Data acquired on
sex diﬀerences in absorption, distribution, metabolism and
elimination allow exploration of sex diﬀerences in disposi-
tion and response to chemicals and drugs. Results from clin-
ical trials focusing on HIV-infected female subjects have sug-
gested that there are clinically relevant sex-related diﬀerences
in the eﬃcacy and safety of drug treatment (Table 4)[ 114].10 Journal of Biomedicine and Biotechnology
6. Conclusions
Males and females may diﬀer in speciﬁc drug pharmacoki-
netics and pharmacodynamics. It is, therefore, essential to
understand those sex diﬀerences in drug disposition and
response, as they may aﬀect drug safety and eﬀectiveness. To
minimizetherapeuticadverseevents,cliniciansandthephar-
maceuticalindustrymustestablishcleartherapeuticgoalsfor
the drugs of choice prior to treatment of women. It must be
determined if the treatment should be assessed by clinical
signs and symptoms or by laboratory test results whether
drug toxicity will be evaluated by clinical or laboratory
assessment, and what determines the appropriate duration
of treatment. Furthermore, clinicians should be aware of
and understand the principles of clinical pharmacology and
absorption,disposition, metabolism,andeliminationasthey
apply to the drug of choice. In particular, the prescribing
physician should understand the relationship between drug
dose, drug concentration and desired biological eﬀect at
the action site, the mechanism of action of the drug, the
impact of the chosen drug on the patient’s signs, symptoms
of adverse eﬀects, and laboratory testing.
In general, data on sex diﬀerences are mostly obtained
by post hoc analysis; therefore, the conclusions that can be
drawn are limited. For a better understanding of the basic
mechanisms of sex diﬀerences, future large-scale prospective
studies should be designed with a primary focus on this
topic. Although we have been able to articulate many of
the sex diﬀerences in drug absorption, metabolism, and
elimination, it is still necessary to identify the speciﬁc ADRs
these diﬀerences can lead to as well as the mechanisms
behind diﬀerences seen in pharmacokinetics and pharma-
codynamics between the sexes. In particular, the potential
for competitive hormone-drug interactions could provide us
with more detailed mechanisms behind the pharmacokinetic
diﬀerences seen between sexes. Further genetic studies in
the context of drug toxicity and ADRs would contribute
to our understanding of gender-speciﬁc pharmacokinetics.
More speciﬁc data will help to determine the extent to
which these diﬀerences will have implications for clinical
management.
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